Global Crisaborole Market Roadmap to 2031

Market Overview

The Crisaborole Market is an emerging segment of the dermatology and pharmaceutical industry, centered on treatments for inflammatory skin conditions, particularly atopic dermatitis. Crisaborole is a topical phosphodiesterase-4 (PDE4) inhibitor designed to help manage inflammation through a non-steroidal treatment approach.

The market includes prescription topical formulations, branded dermatology products, potential generic alternatives, and distribution through hospitals, dermatology clinics, retail pharmacies, and online pharmacy channels. Demand is supported by the increasing prevalence and diagnosis of atopic dermatitis, greater awareness of chronic skin diseases, and growing interest in steroid-free treatment options.

A key feature of the market is the increasing emphasis on targeted and patient-friendly dermatological therapies. Physicians and patients are seeking treatments that can be incorporated into long-term disease-management strategies while addressing concerns associated with repeated corticosteroid use.

Key Players

• Pfizer – Markets EUCRISA® (crisaborole) in the United States.
• Anacor Pharmaceuticals – Originally developed crisaborole before its acquisition by Pfizer.
• Amgen – Acquired Horizon Therapeutics, which holds commercialization rights for crisaborole in certain markets.
• LGM Pharma – Has announced development and manufacturing capabilities related to pharmaceutical formulations and active ingredients.
• Generic and specialty pharmaceutical manufacturers – May participate as patent, regulatory, and market-access conditions evolve.

Market Trend

The market is increasingly shaped by demand for non-steroidal and targeted topical therapies for inflammatory skin diseases. Crisaborole offers a treatment option based on PDE4 inhibition rather than topical corticosteroid activity.

Another important trend is the growing focus on personalized dermatology and long-term disease management. Treatment decisions are increasingly influenced by disease severity, patient age, treatment history, tolerability, convenience, and access to alternative therapies.

The competitive landscape is also evolving as dermatology treatment increasingly includes biologics, JAK inhibitors, topical PDE4 inhibitors, and other advanced therapies. This is encouraging pharmaceutical companies to differentiate products based on clinical evidence, safety, formulation, pricing, and patient access.

Market Driver

One of the strongest drivers is the growing demand for non-steroidal treatments for atopic dermatitis. Crisaborole, marketed in the U.S. as EUCRISA®, is a topical PDE4 inhibitor indicated for mild-to-moderate atopic dermatitis in adults and pediatric patients aged 3 months and older.

The increasing focus on long-term management of chronic inflammatory skin conditions is also supporting market development. Patients and healthcare providers have access to an expanding range of treatment options, creating demand for therapies that can address different levels of disease severity and individual treatment needs.

Additional drivers include greater awareness of dermatological conditions, improved diagnosis, expansion of specialist dermatology services, and the continued development of advanced topical and systemic therapies.

Market Opportunity

The market presents opportunities in the development and commercialization of new formulations, improved patient-access programs, and broader geographic availability of crisaborole-based therapies. Pediatric dermatology is also an important segment because EUCRISA is approved for patients as young as 3 months.

Another opportunity lies in improving treatment convenience and adherence. The current U.S. prescribing information allows consideration of once-daily application after a clinical effect has been achieved with twice-daily treatment, potentially supporting more flexible long-term treatment strategies.

As pharmaceutical competition increases, companies may also explore differentiated approaches involving patient support, digital engagement, dermatology-focused distribution, and improved market access.

Regional Analysis

North America represents a key market for crisaborole because of its established dermatology sector, high healthcare expenditure, broad availability of prescription treatments, and the presence of EUCRISA in the U.S. market. Pfizer continues to provide prescribing, efficacy, and patient-support information for the product.

Europe remains an important potential market for advanced dermatology therapies due to strong healthcare infrastructure and growing adoption of targeted treatments for inflammatory skin diseases. Market access, pricing, and regulatory decisions can significantly influence the availability of individual products.

Asia-Pacific offers long-term growth potential because of its large patient population, expanding healthcare infrastructure, rising dermatology awareness, and increasing availability of specialty pharmaceutical products.

Latin America, the Middle East, and Africa represent emerging opportunities as access to dermatology specialists and advanced prescription therapies continues to expand.

Recent Developments

The crisaborole market continues to be influenced by the broader evolution of the atopic dermatitis treatment landscape. Pfizer’s current EUCRISA information highlights expanded dosing flexibility, allowing consideration of once-daily application after clinical response is achieved with twice-daily treatment.

Long-term treatment data also remain an important area of product positioning. A Phase 3 study evaluated once-daily EUCRISA over a 52-week period in patients who had previously responded during an open-label treatment phase.

Meanwhile, competition in atopic dermatitis is intensifying through continued innovation in biologics, JAK inhibitors, and other targeted therapies. In 2026, Pfizer also reported positive Phase 2 results for its investigational trispecific antibody tilrekimig in moderate-to-severe atopic dermatitis, illustrating the continued expansion of the broader dermatology innovation pipeline.

Key market challenges include product pricing, reimbursement limitations, competition from alternative topical and systemic therapies, patient adherence, and the need to demonstrate differentiation within an increasingly competitive atopic dermatitis treatment market.

Conclusion

The Crisaborole Market represents a specialized but important segment of the dermatology pharmaceutical industry, supported by demand for non-steroidal topical treatment options for mild-to-moderate atopic dermatitis.

Future market development will depend on factors such as patient access, reimbursement, treatment convenience, geographic expansion, clinical differentiation, and competition from newer targeted dermatology therapies. Companies operating in this area will increasingly compete on clinical evidence, affordability, patient support, and their ability to address the evolving needs of dermatology patients.